Lead Discovery and the Concepts of Complexity and Lead-Likeness in the Evolution of Drug Candidates
Mike Hann(GlaxoSmithKline (United Kingdom)), Ed Griffen(AstraZeneca (United Kingdom)), Andrew R. Leach(LifeArc), Jeremy N. Burrows(AstraZeneca (Sweden))
Cited by 7
Related Papers
Development and validation of a genetic algorithm for flexible docking 1 1Edited by F. E. Cohen
|Journal of Molecular Biology|1997|6.7k
ChEMBL: towards direct deposition of bioassay data
|Nucleic Acids Research|2018|2.5k
The ChEMBL database in 2017
|Nucleic Acids Research|2016|2.4k
Molecular Modelling: Principles and Applications
|Unknown|1996|1.9k
An analysis of the attrition of drug candidates from four major pharmaceutical companies
|Nature Reviews Drug Discovery|2015|1.4k